Population-based analysis of invasive fungal infections, France, 2001-2010

Emerging Infectious Diseases

Volumn 20, Issue 7, 2014, Pages 1149-1155

  Bitar, Dounia ^a   Lortholary, Olivier ^b,c,d   Le Strat, Yann ^a   Nicolau, Javier ^a   Coignard, Bruno ^a   Tattevin, Pierre ^e   Che, Didier ^a   Dromer, Françoise ^b,c  

^a Insitut de Veille Sanitaire   (France)

^b INSTITUT PASTEUR   (France)

^c CNRS   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e Pontchaillou University   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CANDIDEMIA; CRYPTOCOCCOSIS; DIABETES MELLITUS; FEMALE; FRANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INVASIVE ASPERGILLOSIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORBIDITY; MORTALITY; MUCORMYCOSIS; NEWBORN; NONHUMAN; ORGAN TRANSPLANTATION; PNEUMOCYSTIS JIROVECI; PNEUMOCYSTIS PNEUMONIA; RISK FACTOR; SOLID TUMOR; SYSTEMIC MYCOSIS; TREND STUDY; VERY ELDERLY; ASPERGILLOSIS; HEMATOLOGIC NEOPLASMS; MICROBIOLOGY; MYCOSES; PNEUMONIA, PNEUMOCYSTIS;

ADULT; AGED; ASPERGILLOSIS; CANDIDEMIA; CRYPTOCOCCOSIS; FEMALE; FRANCE; HEMATOLOGIC NEOPLASMS; HIV INFECTIONS; HOSPITAL MORTALITY; HUMANS; MALE; MIDDLE AGED; MYCOSES; PNEUMOCYSTIS JIROVECII; PNEUMONIA, PNEUMOCYSTIS; RISK FACTORS;

EID: 84902829894     PISSN: 10806040     EISSN: 10806059     Source Type: Journal    
DOI: 10.3201/eid2007.140087     Document Type: Article

References (33)

1. Patterson TF. Advances and challenges in management of invasive mycoses. Lancet. 2005;366:1013-25. http://dx.doi.org/10.1016/ S0140-6736(05)67381-3
2. Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman CA, Freifeld A, et al. Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis. 2010;50:1101-11. http://dx.doi.org/10.1086/651262
3. McNeil MM, Nash SL, Hajjeh RA, Phelan MA, Conn LA, Plikaytis BD, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis. 2001;33:641-7. http://dx.doi.org/10.1086/322606
4. Maschmeyer G. The changing epidemiology of invasive fungal infections: new threats. Int J Antimicrob Agents 2006;27(Suppl 1):3-6. http://dx.doi.org/10.1016/j.ijantimicag.2006.03.006
5. Dromer F, Mathoulin-Pelissier S, Fontanet A, Ronin O, Dupont B, Lortholary O. on behalf of the French Cryptococcosis Study Group. Epidemiology of HIV-associated cryptococcosis in France (1985-2001): comparison of the pre- and post-HAART eras. AIDS. 2004;18:555-62. http://dx.doi.org/10.1097/00002030- 200402200-00024
6. Morris A, Lundgren JD, Masur H, Walzer PD, Hanson DL, Frederick T, et al. Current epidemiology of Pneumocystis pneumonia. Emerg Infect Dis. 2004;10:1713-20. http://dx.doi.org/10.3201/eid1010.030985
7. Rees JR, Pinner RW, Hajjeh RA, Brandt ME, Reingold AL. The epidemiological features of invasive mycotic infections in the San Francisco Bay area, 1992-1993: results of population-based laboratory active surveillance. Clin Infect Dis. 1998;27:1138-47. http://dx.doi.org/10.1093/clinids/27.5.1138
8. Menzin J, Meyers JL, Friedman M, Korn JR, Perfect JR, Langston AA et al. The economic costs to United States hospitals of invasive fungal infections in transplant patients. Am J Infect Control. 2011;39:e15-20. http://dx.doi.org/10.1016/j.ajic.2010. 06.009
9. Lamagni TL, Evans BG, Shigematsu M, Johnson EM. Emerging trends in the epidemiology of invasive mycoses in England and Wales (1990-9). Epidemiol Infect. 2001;126:397-414. http://dx.doi. org/10.1017/S0950268801005507
10. Brown GD, Denning DW, Levitz SM. Tackling human fungal infections. Science. 2012;336:647. http://dx.doi.org/10.1126/science.1222236
11. Direction de la recherche, des études, de l'évaluation et des statistiques (DREES). Le panorama des établissements de santé. Paris: DREES; 2011.
12. Bitar D, Morizot G, Vancauteren D, Dannaoui E, Lanternier F, Lortholary O, et al. Estimating the burden of mucormycosis infections in France (2005-2007) through a capture-recapture method on laboratory and administrative data. Rev Epidemiol Sante Publique. 2012;60:383-7. http://dx.doi.org/10.1016/j.respe.2012.03.007
13. Royston P, Ambler G, Sauerbrei W. The use of fractional polynomials to model continuous risk variables in epidemiology. Int J Epidemiol. 1999;28:964-74. http://dx.doi.org/10.1093/ije/28.5.964
14. Bitar D, Vancauteren D, Lanternier F, Dannaoui E, Che D, Dromer F, et al. Increasing incidence of zygomycosis (mucormycosis), France, 1997-2006. Emerg Infect Dis. 2009;15:1395-401. http://dx.doi. org/10.3201/eid1509.090334
15. Lanternier F, Dannaoui E, Morizot G, Elie C, Garcia-Hermoso D, Huerre M, et al. A global analysis of mucormycosis in France: the RetroZygo Study (2005-2007). Clin Infect Dis. 2012;54(Suppl 1):S35-43. http://dx.doi.org/10.1093/cid/cir880
16. Chang DC, Burwell LA, Lyon GM, Pappas PG, Chiller TM, Wannemuehler KA, et al. Comparison of the use of administrative data and an active system for surveillance of invasive aspergillosis. Infect Control Hosp Epidemiol. 2008;29:25-30. http://dx.doi. org/10.1086/524324
17. Menzin J, Meyers JL, Friedman M, Perfect JR, Langston AA, Danna RP, et al. Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients. Am J Health Syst Pharm. 2009;66:1711-7. http://dx.doi.org/10.2146/ajhp080325
18. Zilberberg MD, Shorr AF, Kollef MH. Secular trends in candidemiarelated hospitalization in the United States, 2000-2005. Infect Control Hosp Epidemiol. 2008;29:978-80. http://dx.doi. org/10.1086/591033
19. Sandven P, Bevanger L, Digranes A, Haukland HH, Mannsaker T, Gaustad P. Candidemia in Norway (1991 to 2003): results from a nationwide study. J Clin Microbiol. 2006;44:1977-81. http://dx.doi. org/10.1128/JCM.00029-06
20. Poikonen E, Lyytikainen O, Anttila VJ, Koivula I, Lumio J, Kotilainen P, et al. Secular trend in candidemia and the use of fluconazole in Finland, 2004-2007. BMC Infect Dis. 2010;10:312 http://dx.doi.org/10.1186/1471-2334-10-312.
21. Laupland KB, Gregson DB, Church DL, Ross T, Elsayed S. Invasive Candida species infections: a 5 year population-based assessment. J Antimicrob Chemother. 2005;56:532-7. http://dx.doi.org/10.1093/ jac/dki258
22. Asmundsdóttir LR, Erlendsdottir H, Gottfredsson M. Increasing incidence of candidemia: results from a 20-year nationwide study in Iceland. J Clin Microbiol. 2002;40:3489-92. http://dx.doi. org/10.1128/JCM.40.9.3489-3492.2002
23. Dasbach EJ, Davies GM, Teutsch SM. Burden of aspergillosisrelated hospitalizations in the United States. Clin Infect Dis. 2000;31:1524-8. http://dx.doi.org/10.1086/317487
24. Dromer F, Mathoulin-Pelissier S, Launay O, Lortholary O. Determinants of disease presentation and outcome during cryptococcosis: the CryptoA/D study. PLoS Med. 2007;4:e21. http://dx.doi. org/10.1371/journal.pmed.0040021
25. Kelley CF, Checkley W, Mannino DM, Franco-Paredes C, Del Rio C, Holguin F. Trends in hospitalizations for AIDSassociated Pneumocystis jirovecii pneumonia in the United States (1986 to 2005). Chest. 2009;136:190-7. http://dx.doi.org/10.1378/ chest.08-2859
26. Maini R, Henderson KL, Sheridan EA, Lamagni T, Nichols G, Delpech V, et al. Increasing Pneumocystis pneumonia, England, UK, 2000-2010. Emerg Infect Dis. 2013;19:386-92.
27. Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, et al. Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis. 2010;50:1091-100. http://dx.doi.org/10.1086/651263
28. Azie N, Neofytos D, Pfaller M, Meier-Kriesche HU, Quan SP, Horn D. The PATH (Prospective Antifungal Therapy) Alliance registry and invasive fungal infections: update 2012. Diagn Microbiol Infect Dis. 2012;73:293-300. http://dx.doi. org/10.1016/j.diagmicrobio.2012.06.012
29. Horn DL, Fishman JA, Steinbach WJ, Anaissie EJ, Marr KA, Olyaei AJ, et al. Presentation of the PATH Alliance registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections. Diagn Microbiol Infect Dis. 2007;59:407-14. http://dx.doi.org/10.1016/j.diagmicrobio. 2007.06.008
30. Alangaden GJ. Nosocomial fungal infections: epidemiology, infection control, and prevention. Infect Dis Clin North Am. 2011;25:201-25. http://dx.doi.org/10.1016/j.idc.2010.11.003
31. Neblett Fanfair R, Benedict K, Bos J, Bennett SD, Lo YC, Adebanjo T, et al. Necrotizing cutaneous mucormycosis after a tornado in Joplin, Missouri, in 2011. N Engl J Med. 2012;367:2214-25. http://dx.doi.org/10.1056/NEJMoa1204781
32. Kainer MA, Reagan DR, Nguyen DB, Wiese AD, Wise ME, Ward J, et al. Fungal infections associated with contaminated methylprednisolone in Tennessee. N Engl J Med. 2012;367:2194-203. http://dx.doi.org/10.1056/NEJMoa1212972
33. Al-shair K, Atherton GT, Harris C, Ratcliffe L, Newton PJ, Denning DW. Long-term antifungal treatment improves health status in patients with chronic pulmonary aspergillosis: a longitudinal analysis. Clin Infect Dis. 2013;57:828-35. http://dx.doi. org/10.1093/cid/cit411